A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE3

מצבים רפואיים

Moderately to Severely Active Ulcerative Colitis

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • University of South Florida, Tampa, Florida, United States

  • Children's Healthcare of Atlanta, Atlanta, Georgia, United States

  • NYU Langone Health, New York, New York, United States

  • Mater Hospital Brisbane, South Brisbane, Queensland, Australia

  • Royal Children's Hospital, Parkville, Victoria, Australia

  • Perth Children's Hospital, Nedlands, Western Australia, Australia

  • Children's Hospital ZheJiang University School of Medicine, Hangzhou, Zhejiang, China

  • Emmed Research, Pretoria, South Africa

  • National Taiwan University Hospital, Taipei, Taiwan

  • Chulalongkorn University, Bangkok, Thailand

  • Siriraj Hospital, Bangkok, Thailand

  • Ramathibodi Hospital, Bangkok, Thailand

  • Birmingham Children's Hospital, Birmingham, United Kingdom

  • Addenbrooke's Hospital, Cambridge, United Kingdom

  • Sheffield Childrens Hospital, Sheffield, United Kingdom

מובילי המחקר
  • Clinical Trials

    Study Director

    Hoffmann-La Roche